Physical health and schizophrenia

Current Opinion in Psychiatry

Volumn 19, Issue 4, 2006, Pages 432-437

  Mitchell, Alex J ^a   Malone, Darren ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Atypical antipsychotics; Cardiovascular disease; Cerebrovascular disease; Diabetes; Hyperlipidaemia; Medical comorbidity; Metabolic syndrome; Osteoporosis; Physical illness; Prevention; Schizophrenia

Indexed keywords

BUTYROPHENONE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; PIPAMPERONE; RISPERIDONE; THIORIDAZINE;

BODY WEIGHT DISORDER; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; HEALTH CARE QUALITY; HEALTH PROMOTION; HEALTH STATUS; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HUMAN; LIPIDOSIS; MEDICAL CARE; MENTAL HEALTH; MENTAL HEALTH CARE; MENTAL PATIENT; METABOLIC SYNDROME X; MYOCARDITIS; NONHUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; WEIGHT GAIN;

EID: 33748270039     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Jones DR, Macias C, Barreira PJ, et al. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv 2004; 55:1250-1257.
2. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26:903-912.
3. Heila H, Haukka J, Suvisaari J, Lonnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 2005; 35:725-732. This is the latest in a series of papers to examine mortality in schizophrenia. In this study, the authors used an impressive national hospital database and calculated relative risks for mortality not only due to natural causes but also due to unnatural causes (accident, homicide and suicide). Patients with schizophrenia had an increased mortality from both natural causes and suicide. The relative risk for both natural and unnatural deaths was highest among patients with a recent onset of schizophrenia (less than 5 years).
4. Joukamaa M, Heliovaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 18:122-127. The authors conducted a 17-year follow-up study on a population sample of 7217 Finns aged 30 years or older. The relative mortality risk between those with schizophrenia and others was 2.25 even after adjusting for physical disease and risk factors. The number of antipsychotics used at the time of the baseline survey showed a graded relationship with mortality. This suggests that risk factors alone (as measured) do not explain all excess risk. Antipsychotic use was not examined by dose or duration and could be confounded by disease severity.
5. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150:1115-1121. In a focused literature review the authors reiterate that the average life expectancy of the general Western population is 76 years (72 years in men, 80 years in women), whereas the corresponding figure is 61 years (57 years in men, 65 years in women) among patients with schizophrenia and that patients with schizophrenia have approximately a 20% reduced life expectancy compared with the general population.
6. Dickey B, Normand S-L, Weiss R, et al. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv 2002; 53:861-867.
7. Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Adv Psychiatr Treat 2005; 11:125-132.
8. McCreadie RG. Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183:534-539.
9. Daumit GL, Goldberg RW, Anthony C, et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis 2005; 193:641-646.
10. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 (Suppl 7):22-31.
11. Allison DB, Mackell JA, Mcdonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54:565-567.
12. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005; 80:9-18. In this US$42.6-million National Institute of Mental Health study, a remarkable 74% of patients discontinued their antipsychotic medication over an 18-month period, in spite of monthly monitoring. Baseline and follow-up metabolic data for patients were collected and results continue to be analysed. Interestingly, there were no significant differences between patients with and without metabolic syndrome on measures of symptom severity, depression, quality of life or self-rated mental health. Many cite CATIE metabolic data, although they are not well described in the index of The New England Journal of Medicine publication.
13. Lieberman J, McEvoy JP, Perkins D, Hamer RH. Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone. Eur Neuropsychopharmacol 2005; 15 (Suppl 3):S525 [abstract P.3.163].
14. Straker D, Correll CU, Kramer-Ginsberg E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005; 162:1217-1221.
15. Saari KM, Lindeman SM, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005; 66:559-563. In an impressive study the authors examined 5613 members of the Northern Finland 1966 Birth Cohort divided into those with schizophrenia, other functional psychoses, nonpsychotic disorders and no psychiatric hospital treatment (n = 5455, comparison group). Participants were assessed for the presence of metabolic syndrome, according to the criteria of the National Cholesterol Education Program. The prevalence of metabolic syndrome was higher in patients with schizophrenia compared with the comparison group (19 vs 6%, P = 0.010). Similar large-scale analyses are awaited in other populations.
16. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70:1-17.
17. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (Suppl 18):27-35.
18. Saari K, Jokelainen J, Veijola J, et al. Serum lipids in schizophrenia and other functional psychoses: a general population Northern Finland 1966 Birth Cohort survey. Acta Psychiatr Scand 2004; 110:279-285.
19. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59:1021-1026.
20. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998; 338:1516-1520.
21. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71:195-212.
22. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005; 66:504-514.
23. Ananth J, Venkatesh R, Burgoyne K, et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002; 71:244-254.
24. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66:1116-1121. The prolific Henderson group studied 96 patients on clozapine. The Kaplan-Meier estimate for 10-year mortality from cardiovascular disease was 9%. African American and Hispanic American patients exhibited elevated risk of cardiovascular disease-related mortality (OR = 7.2, P = 0.09 and OR = 11.3, P = 0.04, respectively) compared with White patients. This is one of the few papers of metabolic effects with long-term outcome data.
25. Lamberti JS, Costea GO, Olson D, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. J Clin Psychiatry 2005; 66:900-906.
26. Zhang Z-J, Yao Z-J, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004; 184:58-62.
27. Dwyer DS, Donohoe D, Lu XH, Aamodt EJ. Mechanistic connections between glucose/lipid disturbances and weight gain induced by antipsychotic drugs. Int Rev Neurobiol 2005; 65:211-247. This paper thoroughly reviews the possible mechanisms underlying metabolic disturbance. The authors suggest that the operation of the glucose-fatty acid cycle and the cooperative regulation of energy metabolism at the level of signalling pathways, including Akt and AMP-activated protein kinase which converge on forkhead and CCAAT/enhancer- binding protein (C/EBP) transcription factors, are a key. Helpfully they also review data from animal models.
28. Cooper GD, Pickavance LC, Wilding JPH, et al. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology 2005; 181:80-89. The authors suggest that olanzapine-induced hyperphagia acts as an initial stimulus that leads to weight gain, enhanced visceral adiposity and subsequent insulin resistance, although the latter may be ameliorated by compensatory catabolic responses to some extent.
29. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62:19-28. Thirty-six nonobese patients with schizophrenia, or schizoaffective disorder, matched by BMI and treated with clozapine, olanzapine or risperidone, underwent detailed metabolic assessment. Fasting seruminsulin concentrations differed among groups. The homeostasis model assessment of insulin resistance also differed as did measures of glucose effectiveness. In all models, clozapine was worse than olanzapine, which in turn was worse than risperidone. This is an important head-to-head comparison with the most thorough metabolic testing to date.
30. Best L, Yates AP, Reynolds GP. Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol. J Psychopharmacol 2005; 19:597-601.
31. Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan. Canada J Clin Psychiatry 2004; 65:715-720.
32. Straus SMJM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004; 164:1293-1297.
33. Liperoti R, Gambassi G, Lapane KL, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 2005; 165:696-701. The authors conducted a case-control study (649 cases and 2962 controls) on residents of nursing homes in six US states by using data from Medicare inpatient claims. Cases were residents hospitalized for ventricular arrhythmias or cardiac arrest. Use of conventional antipsychotics was associated with a nearly twofold increase in risk of hospitalization for ventricular arrhythmias or cardiac arrest (adjusted OR, 1.86; 95% confidence interval, 1.27-2.74). No increased risk associated with the use of atypical antipsychotics was noted (OR, 0.87; 95% confidence interval, 0.58-1.32). The risk of hospitalization for ventricular arrhythmias or cardiac arrest was highest among conventional users with cardiac disease.
34. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25:32-41.
35. Abdelmawla N, Mitchell AJ. Sudden cardiac death and antipsychotics. Part I - Risk factors and mechanisms. Adv Psychiatr Treat 2006; 12:35-44. In this review article, the authors examine the recent evidence pertaining to sudden death in those taking antipsychotics. Most antipsychotics prolong the QTc interval in overdose but some prolong it even at therapeutic doses. The authors conclude that there is only an approximate relationship between QT prolongation and risk of sudden death. Risk is modified by preexisting cardiac disease, those taking multiple QT-acting drugs and those taking high dose of antipsychotics for long periods.
36. Naidoo U, Goff DC, Klibanski A. Hyperprolactinaemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28:97-108.
37. Hugenholtz GWK, Heerdink ER, van Staa TP, et al. Risk of hip/femur fractures in patients using antipsychotics. Bone 2005; 37:864-870. The authors conducted a rare case-control study of 44 500 patients taking vs not taking antipsychotics. Both current and prior use of antipsychotics were associated with an approximately twofold increased risk of fractures. After adjustment for possible confounders, a small significant effect remained (OR, 1.3). The total number of days of antipsychotic use was significantly associated with an increased risk of hip/femur fractures.
38. Dombrovski A, Rosenstock J. Bridging general medicine and psychiatry: providing general medical and preventive care for the severely mentally ill. Curr Opin Psychiatry 2004; 17:523-529.
39. Jones LE, Clarke W, Carney CP. Receipt of diabetes services by insured adults with and without claims for mental disorders. Med Care 2004; 42:1167-1175.
40. Dickerson FB, Brown CH. Somatic healthcare utilization among adults with serious mental illness who are receiving community psychiatric services. J Med Care 2003; 41:560-570.
41. Druss BG, Perlin JB. Quality of preventative medical care for patients with mental disorders. J Med Care 2002; 40:129-136.
42. Druss BG, Bradford D, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58:565-572.
43. Jones LE, Clarke W, Carney CP. Receipt of diabetes services by insured adults with and without claims for mental disorders. Med Care 2004; 42:1167-1175.
44. Desai MM, Rosenheck RA, Druss BG, Perlin JB. Mental disorders and quality of diabetes care in the veterans health administration. Am J Psychiatry 2002; 159:1584-1590.
45. Bishop JR, Alexander B, Lund B, et al. Osteoporosis screening and treatment in women with schizophrenia: a controlled study. Pharmacotherapy 2004; 24:515-521.
46. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24:S1-S6.
47. Buckley PF, Miller DD, Singer B, et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79:281-288. Respondents indicated awareness of the risks of treatment with atypical antipsychotics. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation.
48. Chwastiak L, Rosenheck R, Leslie D. Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample. Med Care 2006; 44:55-61. The authors examined all veterans affairs outpatients diagnosed with schizophrenia during 2002 for nine chronic medical conditions. Measures of quality of schizophrenia pharmacotherapy were based on the Schizophrenia PORT. Patients with six of the nine chronic medical conditions were significantly less likely to be prescribed antipsychotic medications, and the odds of this treatment decreased with increasing medical complexity. Of the patients, 63.8% received doses that were within the recommended PORT guidelines.
49. Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005; 19:102-109.
50. Melkersson KI, Dahl ML, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology 2004; 175:1-6.
51. Abdelmawla N, Mitchell AJ. Sudden cardiac death and antipsychotics. Part 2: Monitoring and prevention. Adv Psychiatr Treat 2006; 12:100-109. In an extension to the previously mentioned paper, the authors attempt to suggest guidelines on clinical monitoring of cardiovascular health for those prescribed antipsychotic medication. Other such guidance is needed in relation to other areas of physical health.
52. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349.
53. McCreadie RG, Kelly C, Connolly M, et al. Dietary improvement in people with schizophrenia: randomised controlled trial. Br J Psychiatry 2005; 187:346-351. In this innovative work researchers randomly allocated 102 people with schizophrenia in two areas of Scotland to receive free fruits and vegetables for 6 months, supported by instruction in meal planning and food preparation; to receive free fruits and vegetables alone; or to continue as before. Those who received free fruits and vegetables or free fruits and vegetables and associated instruction were consuming significantly more fruits and vegetables than those in the treatment as usual group. Consumption fell to preintervention levels 12 months after the intervention stopped. No between-group difference, however, was noted at any time in blood micronutrients, BMI, physical activity or risk of coronary heart disease.
54. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003; 108:324-332.
55. Pendlebury J, Haddad P, Dursun S. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 2005; 20:447-448.
56. Hoffmann VP, Meyers A, Schuh L, et al. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry 2005; 66:1576-1579. Seven thousand one hundred and eighty-eight patients were enrolled in the programme, of whom 83% were either overweight or obese. Follow-up survey responses taken at 6-month endpoint from those who completed (1422) indicated that positive changes were made in diet, exercise, stress and sleep. Significant decreases in BMI were associated with changes in diet (P = 0.014) and exercise (P = 0.035). Of course, those who did not keep up with the follow-up at 6 months are likely to be those who did not manage to lose weight.
57. Conley RR, Shim JC, Kelly DL, et al. Cardiovascular disease in relation to weight in deceased persons with schizophrenia. Compr Psychiatry 2005; 46:460-467. The authors examined autopsy reports for 134 people with schizophrenia and 134 matched normal participants who had died between January 1990 and December 2000 and whose family had donated brain tissue to Maryland Brain Collection. A larger proportion of the schizophrenia group had high (33.3%) and low (20.9%) percentile body weight compared with controls (27.7 vs 10.0%). People with schizophrenia who were underweight had higher rates of cardiac death than the controls (37.7 vs 13%). This is one of the few modern studies to consider underweight issues in patients with SMI.
58. Wolters HA, Knegtering R, Wiersma D, van den Bosch RJ. Evaluation of the Subjects' Response To Antipsychotics Questionnaire. Int Clin Psychopharmacol 2006; 21:63-69.